metformin has been researched along with memantine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abramowitz, W; Chou, T; Rao, N; Ventura, D | 1 |
| Derdau, V; Fromm, MF; König, J; Mertsch, K; Müller, F; Sandvoss, M; Weitz, D | 1 |
| Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW | 1 |
| Nevin, RL | 1 |
| Groves, MD; Maraka, S; Penas-Prado, M | 1 |
| Albayrak, G; Dere, UA; Emmez, H; Konac, E | 1 |
1 review(s) available for metformin and memantine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for metformin and memantine
| Article | Year |
|---|---|
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
Topics: Adult; Alzheimer Disease; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Female; Glyburide; Humans; Male; Memantine; Metformin | 2005 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Mefloquine; Memantine; Metformin; Middle Aged; Progression-Free Survival; Radiotherapy, Adjuvant; Research Design; Temozolomide; Treatment Outcome; Young Adult | 2019 |
10 other study(ies) available for metformin and memantine
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
Topics: Animals; Biological Transport; Cell Line; Cimetidine; Dogs; HEK293 Cells; Humans; Kidney; Madin Darby Canine Kidney Cells; Memantine; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2; Receptors, N-Methyl-D-Aspartate | 2017 |
Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |
Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |
Targeting Cancer Cell Metabolism with Metformin, Dichloroacetate and Memantine in Glioblastoma (GBM).
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dichloroacetic Acid; Dopamine Agents; Dose-Response Relationship, Drug; Glioblastoma; Humans; Hypoglycemic Agents; Memantine; Metformin; Proto-Oncogene Proteins c-bcl-2 | 2021 |